|
12 October, 2023
|
ICON Secures Upgraded Credit Rating from S&P Global Ratings
|
|
|
21 September, 2023
|
ICON plc Schedules Third Quarter 2023 Earnings Conference Call
|
|
|
20 September, 2023
|
ICON Releases Expanded End-to-end Clinical Trial Tokenisation Solution
|
|
|
13 September, 2023
|
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
|
|
|
06 September, 2023
|
ICON plc to Present at the Baird Global Healthcare Conference
|
|
|
26 July, 2023
|
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
|
|
|
26 July, 2023
|
ICON Reports Second Quarter 2023 Results
|
|
|
13 July, 2023
|
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
|
|
|
27 June, 2023
|
ICON plc Schedules Second Quarter 2023 Earnings Conference Call
|
|
|
26 June, 2023
|
ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
|
|
|
26 June, 2023
|
ICON plc Set to Join Russell 3000® Index
|
|
|
31 May, 2023
|
ICON plc to Attend Upcoming Investor Conferences
|
|
|
16 May, 2023
|
ICON releases its 2022 ICON Cares ESG Report
|
|
|
26 April, 2023
|
ICON Reports First Quarter 2023 Results
|
|
|
29 March, 2023
|
ICON plc Schedules First Quarter 2023 Earnings Conference Call
|
|
|
10 March, 2023
|
LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology
|
|
|
27 February, 2023
|
ICON plc to Present at Upcoming Investor Conferences
|
|
|
22 February, 2023
|
ICON Reports Fourth Quarter and Full Year 2022 Results
|
|
|
26 January, 2023
|
ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call
|
|
|
10 January, 2023
|
ICON Issues Financial Guidance for Full Year 2023
|
|
